Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study

Zeremski, Vanja; Jentsch-Ullrich, Kathleen; Kahl, Christoph; Mohren, Martin; Eberhardt, Judith; Fischer, Thomas; Schalk, Enrico

doi:10.1007/s00277-019-03819-3

Cited by 10 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systematic review of Cochrane and PubMed database permitted inclusion of 29 studies, and complementary research led to the selection of 3 other studies. Among these 32 studies, there were 6 prospective 13–18 and 26 retrospectives studies 19–44 . There were no comparative and prospective studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review

Briand

Gérard

Gauthier

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL) represents 30%-40% of adult non-Hodgkin lymphoma (NHL). 1 DLBCL is a highly aggressive disease, with a limited life expectancy without treatment and a poor prognosis in case of relapse or refractory disease. 2 Its incidence increases with age, with a median age of 70 years at diagnosis. 1 Considering population aging, an increased incidence is expected within the next few years. 3 R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Oncovin, Prednisone) regimen is widely used as a first-line treatment for this

show abstract

Section: Resultsmentioning

confidence: 99%

“…In other retrospective studies with less intensive treatment, CR varied between 37.2% and 56%. 2‐year OS was 28%–53% 23,27,28,40 …”

Section: Resultsmentioning

confidence: 99%

Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review

Briand

Gérard

Gauthier

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The few studies that do include Merli et al, Olivieri et al, and Spina et al, which focus on dependence in geriatric criteria [ 29 , 30 , 31 ]. There is also the work of Zeremski et al, focusing on chemotherapy in DLBCL in a population with a median age of 79 years, but with ACCI ≥ 6 in only 23% of individuals [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Prescription of Blood Lymphocyte Immunophenotyping in the Diagnosis of Lymphoid Neoplasms in Older Adults

Vovelle¹,

Row

Larosa³

et al. 2022

JCM

View full text Add to dashboard Cite

Lymphoid neoplasms are a heterogeneous group of lymphoid neoplastic diseases with multiple presentations, and varying prognoses. They are especially frequent in older patients (OPs) and the atypism of this frail elderly population can make the diagnostic process even more difficult. Blood lymphocyte immunophenotyping (BLI) is essential in rapid noninvasive diagnosis orientation and guides complementary investigations. To our knowledge, BLI prescription has never been evaluated in OPs. We hypothesized that, when there is a suspicion of lymphoid neoplasm in the geriatric population, a BLI is performed in view of various clinical or biological abnormalities. This study aimed to: (1) describe the characteristics of hospitalized OPs having undergone BLI for suspected lymphoid neoplasm, (2) identify the causes leading to BLI prescription, and (3) identify the most profitable criteria for BLI prescription. This was a descriptive retrospective study on 151 OPs aged ≥75 years who underwent BLI over a 2-year period. Regarding BLI prescriptions, eight had lymphocytosis, constituting the “lymphocytosis group” (LG+), while the 143 others had BLI prescribed for reasons other than lymphocytosis (LG−), mainly general weakness and anemia. In the LG−, we compared OPs with positive and negative BLI results. The criteria found to be profitable for BLI prescription were lymphadenopathy, splenomegaly, lymphocytosis, and thrombocytopenia. BLI identified circulating lymphoid neoplasms (positive BLI) in 21/151 OPs, mainly marginal zone lymphoma and chronic lymphocytic leukemia. In polymorbid OPs, as per our study population, the diagnostic and therapeutic complexity explained in part the sole use of indirect and minimally invasive diagnostic techniques such as BLI.

show abstract

“…Rituximab combined with bendamustine, an intravenous alkylating agent, has been tried in DLBCL [ 76 ]. Retrospective data suggest that it may be a valuable treatment option in older patients [ 77 ]. A recent study reports the case of an 87-year-old woman with large nodules on the legs treated with rituximab plus bendamustine.…”

Section: Aggressive Pcbclmentioning

confidence: 99%

Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives

Dumont

Battistella

Ram‐Wolff

et al. 2020

Cancers

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification differentiates primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma with an indolent course from primary cutaneous diffuse large B-cell lymphoma, leg type with an aggressive behavior. The broad spectrum of clinical presentations and the disease course marked by frequent relapses are diagnostic and therapeutic challenges. The classification of these diseases has been refined in recent years, which allows to better define their immunopathogenesis and specific management. In the present article, we review the main clinico-biological characteristics and the current therapeutic options of these three main subsets. Based on the recent therapeutic advances in nodal B-cell lymphomas, we focus on the development of novel treatment options applicable to primary cutaneous B-cell lymphomas, including targeted therapies, combination treatments and immunotherapeutic approaches, and cover basic, translational and clinical aspects aiming to improve the treatment of cutaneous B-cell lymphomas.

show abstract

Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study

Cited by 10 publications

References 32 publications

Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review

Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review

Prescription of Blood Lymphocyte Immunophenotyping in the Diagnosis of Lymphoid Neoplasms in Older Adults

Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives

Contact Info

Product

Resources

About